Xinbang Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 152 million yuan, a year-on-year decrease of 13.74%
According to the Zhitong Finance APP, Xinbang Pharmaceutical released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 4.266 billion yuan, a year-on-year decrease of 6.55%. The net profit attributable to shareholders of the listed company was 152 million yuan, a year-on-year decrease of 13.74%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 157 million yuan, a year-on-year decrease of 10.50%
According to the Zhitong Finance APP, Xinbang Pharmaceutical (002390.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 4.266 billion yuan, a year-on-year decrease of 6.55%. The net profit attributable to shareholders of the listed company was 152 million yuan, a year-on-year decrease of 13.74%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 157 million yuan, a year-on-year decrease of 10.50%
